Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study

被引：0

作者：

Gruenig, Ekkehard ^{[1
]}

Galie, Nazzareno ^{[2
]}

Humbert, Marc ^{[3
,4
,5
]}

Keogh, Anne M. ^{[6
]}

Langleben, David ^{[7
]}

Rubin, Lewis J. ^{[8
]}

Speich, Rudolf ^{[9
]}

Fritsch, Arno ^{[10
]}

Davie, Neil ^{[10
]}

Ghofrani, Hossein-Ardeschir ^{[11
,12
]}

机构：

[1] Univ Heidelberg Hosp, Thoraxclin, Thoraxclin Heidelberg, Ctr Pulm Hypertens, Heidelberg, Germany

[2] Univ Bologna, Inst Cardiol, Bologna, Italy

[3] Univ Paris 11, Le Kremlin Bicetre, France

[4] INSERM, F-94275 Le Kremlin Bicetre, France

[5] Hop Bicetre, AP HP, Serv Pneumol, Le Kremlin Bicetre, France

[6] St Vincents Hosp, Heart Lung Transplant Unit, Sydney, NSW 2010, Australia

[7] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Pulm Vasc Dis, Montreal, PQ H3T 1E2, Canada

[8] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

[9] Univ Zurich Hosp, Dept Internal Med, Zurich, Switzerland

[10] Bayer HealthCare Pharmaceut, Global Clin Dev, Wuppertal, Germany

[11] Univ Giessen, Dept Internal Med, Giessen, Germany

[12] Marburg Lung Ctr UGMLC, Giessen, Germany

来源：

关键词：

Pulmonary hypertension; Treatments; Nitric oxide;

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

2347

引用

页数：2